Want to see HK:2181 full AI Analyst Report?
Mabpharm Limited (2181) AI Stock Analysis
Mabpharm Limited
(HKEX:2181)
The stock’s score is driven primarily by improving but still fragile financials: rapid revenue growth, high gross margins, and a first year of profitability are offset by a weakened equity base, elevated leverage, and negative free cash flow, keeping risk levels elevated. Technicals are the next most important factor, pointing to a neutral, range‑bound setup where short‑term price action has stabilized but has yet to reverse the longer‑term downtrend. Valuation plays a secondary role with a mid‑20s P/E and no dividend, indicating the shares are not priced for perfection but still rely heavily on the company sustaining its recent turnaround for upside.
Mabpharm Limited (2181) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.77B
- Dividend Yield
- ―
- Average Volume (3M)
- 57.51K
- Price to Earnings (P/E)
- 17.8
- Beta (1Y)
- 0.79
- Revenue Growth
- 88.38%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 394
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Mabpharm Limited Business Overview & Revenue Model
Company Description
Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research, development, and manufacturing of innovative and biosimilar medications. Its therapeutic focus areas include allergic conditions, various cancers, and autoimmune disorder...
How the Company Makes Money
null
Mabpharm Limited Financial Statement Overview
Summary
Revenue has scaled rapidly to 629M with very strong 80–85% gross margins and a first year of positive net income and ROE, but equity has been heavily eroded, leverage is high at ~2.1x debt-to-equity, and free cash flow remains negative despite improved operating cash flow, leaving meaningful balance sheet and cash burn risk typical of an early‑stage biotech.
Income Statement
72PositiveBalance Sheet
55NeutralCash Flow
48Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 764.09M | 629.37M | 258.23M | 87.16M | 55.92M | 82.88M |
| Gross Profit | 652.70M | 521.55M | 219.39M | 75.24M | 40.54M | 66.11M |
| EBITDA | 96.52M | 64.46M | -58.34M | -139.08M | -152.08M | -245.46M |
| Net Income | 84.72M | 55.65M | -127.95M | -209.36M | -210.62M | -291.74M |
Balance Sheet | ||||||
| Total Assets | 1.17B | 1.15B | 1.02B | 1.03B | 917.52M | 899.90M |
| Cash, Cash Equivalents and Short-Term Investments | 93.31M | 109.30M | 89.34M | 173.34M | 48.61M | 81.56M |
| Total Debt | 307.88M | 326.88M | 293.09M | 260.07M | 126.34M | 46.43M |
| Total Liabilities | 974.61M | 996.58M | 927.28M | 829.92M | 516.58M | 297.92M |
| Stockholders Equity | 193.80M | 157.37M | 88.93M | 205.06M | 400.94M | 601.98M |
Cash Flow | ||||||
| Free Cash Flow | 17.82M | -23.22M | -63.58M | 38.35M | -182.01M | -348.14M |
| Operating Cash Flow | 99.49M | 80.78M | -4.10M | 57.39M | -56.88M | -199.47M |
| Investing Cash Flow | -96.63M | -64.16M | -98.20M | -3.50M | -104.95M | -179.42M |
| Financing Cash Flow | -3.69M | 3.29M | 18.28M | 85.60M | 112.26M | -17.78M |
Mabpharm Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2181, the sentiment is Negative. The current price of 0.43 is below the 20-day moving average (MA) of 0.48, below the 50-day MA of 0.45, and below the 200-day MA of 0.46, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 41.63 is Neutral, neither overbought nor oversold. The STOCH value of 12.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2181.
Mabpharm Limited Peers Comparison
Overall Rating
HK:999566Neutral
HK:269664.6Neutral- HK:218163Neutral
HK:996652Neutral
HK:368145Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:9995 | 66Neutral | HKD 51.82B | 7.89 | 105.60% | ― | 292.84% | ― |
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| HK:2181 | 63Neutral | HKD 1.79B | 17.80 | 48.25% | ― | 88.38% | ― |
| HK:9966 | 52Neutral | HKD 6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:3681 | 45Neutral | HKD 1.47B | -6.85 | -41.81% | ― | ― | -4.24% |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2181 | Mabpharm Limited | 0.43 | -0.09 | -16.35% | |
| HK:9966 | Alphamab Oncology | 6.21 | -5.46 | -46.79% | |
| HK:9995 | RemeGen Co. Ltd. Class H | 64.85 | -28.00 | -30.16% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% | |
| HK:3681 | SinoMab Bioscience Ltd. | 1.07 | -0.70 | -39.55% |
Mabpharm Limited Corporate Events
Mabpharm Posts Tenfold Profit Surge on Strong Revenue Growth in First Half 2026
Mabpharm Limited reported a strong interim performance for the six months ended June 30, 2026, with revenue rising 45.1% year-on-year to RMB397.9 million and gross profit increasing 49.9% to RMB361.6 million, reflecting robust sales growth. Profit at...
Mabpharm Sets August Board Meeting to Approve 2026 Interim Results
Mabpharm Limited has scheduled a meeting of its board of directors for August 28, 2026 to review and approve the interim results for the six months ended June 30, 2026. The board session will also address the formal publication of these mid‑yea...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026